PL428485A1 - Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym - Google Patents
Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznymInfo
- Publication number
- PL428485A1 PL428485A1 PL428485A PL42848519A PL428485A1 PL 428485 A1 PL428485 A1 PL 428485A1 PL 428485 A PL428485 A PL 428485A PL 42848519 A PL42848519 A PL 42848519A PL 428485 A1 PL428485 A1 PL 428485A1
- Authority
- PL
- Poland
- Prior art keywords
- substituent
- benzisoxazole
- benzothiophenyl
- group
- alkyl moiety
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- AAPPUPXTZPQMIS-UHFFFAOYSA-N n-(2,5-dioxopyrrolidin-1-yl)-2-phenylacetamide Chemical class O=C1CCC(=O)N1NC(=O)CC1=CC=CC=C1 AAPPUPXTZPQMIS-UHFFFAOYSA-N 0.000 title 1
- -1 -SCF3 Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Przedmiotem zgłoszenia jest związek o wzorze ogólnym (I) lub jego farmaceutycznie akceptowalne sole oraz ich zastosowanie do leczenia chorób o podłożu neurologicznym. We wzorze wyżej wymienionego związku x - oznacza N lub C, k - jest liczbą równą 0 lub 1, A oznacza podstawnik wybrany z grupy zawierającej: podstawnik fenylowy; podstawnik fenylowy podstawiony jednym albo dwoma albo trzema albo czterema podstawnikami bocznymi wybranymi z grupy zawierającej: atomy fluorowców, -SCF3, -CF3, -CHF2, -CN, -OCF3, -NO2, -OCH3, -OC2H5, ugrupowanie alkilowe o ilości atomów węgla szkielecie węglowym od 1 do 4, przy czym ugrupowanie alkilowe ma łańcuch prosty albo rozgałęziony; podstawnik fenylowy podstawiony przynajmniej jednym podstawnikiem aromatycznym albo heteroaromatycznym; podstawnik benzhydrylowy; podstawnik 1-naftalenylowy albo 2-naftalenylowy; podstawnik benzotiofenylowy wybrany z grupy zawierającej podstawniki: 2-benzotiofenylowy, 3-benzotiofenylowy, 4-benzotiofenylowy albo 5-benzotiofenylowy, korzystnie podstawnik 5-benzotiofenylowy; podstawnik benzoizoksazolowy wybrany z grupy zawierającej podstawniki: 3-benzoizoksazolowy, 4-benzoizoksazolowy, 5-benzoizoksazolowy, 6-benzoizoksazolowy, 7-benzoizoksazolowy, korzystnie podstawnik 5-benzoizoksazolowy; ugrupowanie alkilowe o ilości atomów węgla szkielecie węglowym od 1 do 4, przy czym ugrupowanie alkilowe ma łańcuch prosty albo rozgałęziony albo cykliczny, korzystnie ugrupowanie alkilowe jest podstawione przynajmniej jednym atomem fluorowca; B oznacza: podstawnik fenylowy; podstawnik fenylowy podstawiony jednym lub dwoma podstawnikami bocznymi wybranymi z grupy zawierającej: atomy fluorowców, -SCF3, -CF3, -CHF2, -CN, -OCF3, -NO2, -OCH3, -OC2H5, ugrupowanie alkilowe o ilości atomów węgla szkielecie węglowym od 1 do 4, przy czym ugrupowanie alkilowe ma łańcuch prosty albo rozgałęziony.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL428485A PL244071B1 (pl) | 2019-01-07 | 2019-01-07 | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
| AU2020207162A AU2020207162B2 (en) | 2019-01-07 | 2020-01-07 | (2,5-Dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases |
| MX2021008213A MX2021008213A (es) | 2019-01-07 | 2020-01-07 | Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas. |
| CA3125321A CA3125321A1 (en) | 2019-01-07 | 2020-01-07 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases |
| JP2021539610A JP7695884B2 (ja) | 2019-01-07 | 2020-01-07 | （２，５－ジオキソピロリジン－１－イル）（フェニル）－アセトアミド誘導体、および神経疾患の処置におけるその使用 |
| EP20709353.5A EP3908580A1 (en) | 2019-01-07 | 2020-01-07 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases |
| PCT/PL2020/050001 WO2020145831A1 (en) | 2019-01-07 | 2020-01-07 | (2,5-dioxopyrrolidin-l-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases |
| CN202080008108.9A CN113272292B (zh) | 2019-01-07 | 2020-01-07 | (2,5-二氧代吡咯烷-1-基)(苯基)-乙酰胺衍生物及其在治疗神经系统疾病中的用途 |
| US17/309,956 US12139458B2 (en) | 2019-01-07 | 2020-01-07 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases |
| BR112021013406-9A BR112021013406A2 (pt) | 2019-01-07 | 2020-01-07 | Derivados de (2,5-dioxopirrolidin-1-il)(fenil)-acetamida e seu uso no tratamento de doenças neurológicas |
| US18/910,152 US20250109103A1 (en) | 2019-01-07 | 2024-10-09 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases |
| JP2025026065A JP2025081557A (ja) | 2019-01-07 | 2025-02-20 | （２，５－ジオキソピロリジン－１－イル）（フェニル）－アセトアミド誘導体、および神経疾患の処置におけるその使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL428485A PL244071B1 (pl) | 2019-01-07 | 2019-01-07 | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL428485A1 true PL428485A1 (pl) | 2020-07-13 |
| PL244071B1 PL244071B1 (pl) | 2023-11-27 |
Family
ID=69743891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL428485A PL244071B1 (pl) | 2019-01-07 | 2019-01-07 | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12139458B2 (pl) |
| EP (1) | EP3908580A1 (pl) |
| JP (2) | JP7695884B2 (pl) |
| CN (1) | CN113272292B (pl) |
| AU (1) | AU2020207162B2 (pl) |
| BR (1) | BR112021013406A2 (pl) |
| CA (1) | CA3125321A1 (pl) |
| MX (1) | MX2021008213A (pl) |
| PL (1) | PL244071B1 (pl) |
| WO (1) | WO2020145831A1 (pl) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL447254A1 (pl) * | 2023-12-22 | 2025-06-23 | Uniwersytet Jagielloński | Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL244071B1 (pl) * | 2019-01-07 | 2023-11-27 | Univ Jagiellonski | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
| PL244897B1 (pl) * | 2021-11-24 | 2024-03-25 | Univ Jagiellonski | Deuterowane funkcjonalizowane pochodne α-alaniny, zwłaszcza do leczenia chorób neurologicznych |
| CN114920790B (zh) * | 2022-04-28 | 2024-06-14 | 康龙化成(宁波)科技发展有限公司 | 一种寡聚核酸-二酰亚胺化合物的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO121085B1 (ro) * | 1999-12-01 | 2006-12-29 | Ucb, S.A., | Utilizarea levetiracetamului, în tratamentul bolilor sistemului nervos central |
| CN1484527A (zh) * | 2000-12-28 | 2004-03-24 | ��һ��������ҩ��ʽ���� | 神经性疼痛治疗和预防药 |
| JP2005534632A (ja) * | 2002-05-10 | 2005-11-17 | ニューロクライン バイオサイエンセズ， インコーポレイテッド | メラノコルチンレセプターリガンドとしての置換ピペラジン |
| US20050119252A1 (en) * | 2003-10-22 | 2005-06-02 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US9567302B2 (en) * | 2012-03-19 | 2017-02-14 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| PL244071B1 (pl) * | 2019-01-07 | 2023-11-27 | Univ Jagiellonski | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
-
2019
- 2019-01-07 PL PL428485A patent/PL244071B1/pl unknown
-
2020
- 2020-01-07 EP EP20709353.5A patent/EP3908580A1/en active Pending
- 2020-01-07 JP JP2021539610A patent/JP7695884B2/ja active Active
- 2020-01-07 CN CN202080008108.9A patent/CN113272292B/zh active Active
- 2020-01-07 CA CA3125321A patent/CA3125321A1/en active Pending
- 2020-01-07 BR BR112021013406-9A patent/BR112021013406A2/pt unknown
- 2020-01-07 AU AU2020207162A patent/AU2020207162B2/en active Active
- 2020-01-07 US US17/309,956 patent/US12139458B2/en active Active
- 2020-01-07 WO PCT/PL2020/050001 patent/WO2020145831A1/en not_active Ceased
- 2020-01-07 MX MX2021008213A patent/MX2021008213A/es unknown
-
2024
- 2024-10-09 US US18/910,152 patent/US20250109103A1/en active Pending
-
2025
- 2025-02-20 JP JP2025026065A patent/JP2025081557A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL447254A1 (pl) * | 2023-12-22 | 2025-06-23 | Uniwersytet Jagielloński | Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113272292A (zh) | 2021-08-17 |
| JP2025081557A (ja) | 2025-05-27 |
| WO2020145831A1 (en) | 2020-07-16 |
| JP2022522949A (ja) | 2022-04-21 |
| US20220073461A1 (en) | 2022-03-10 |
| AU2020207162B2 (en) | 2025-03-20 |
| AU2020207162A1 (en) | 2021-07-15 |
| BR112021013406A2 (pt) | 2021-09-14 |
| JP7695884B2 (ja) | 2025-06-19 |
| CN113272292B (zh) | 2024-04-12 |
| EP3908580A1 (en) | 2021-11-17 |
| CA3125321A1 (en) | 2020-07-16 |
| US20250109103A1 (en) | 2025-04-03 |
| PL244071B1 (pl) | 2023-11-27 |
| MX2021008213A (es) | 2021-08-11 |
| WO2020145831A8 (en) | 2021-07-15 |
| US12139458B2 (en) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220062A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina | |
| YU48780B (sh) | Derivati 4-benzoilizoksazola, postupci za njihovo dobijanje, herbicidni preparati koji sadrže pomenute derivate i postupak za kontrolu rasta korova | |
| BRPI0613403A2 (pt) | tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina | |
| BRPI0413283B8 (pt) | Composto derivado de (tio)carbamoil-ciclohexano, seu processo de preparação, amina, composição farmacêutica e uso do composto | |
| MEP10009A (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-hpyrrole derivatives as acid secretion inhibitors | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| MY149180A (en) | Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof | |
| EP2597088A4 (en) | P2X4 Receptor Antagonists | |
| BR112019021853A2 (pt) | Compostos de inibidor de vmat2 e composições dos mesmos | |
| EA201591000A1 (ru) | Пирролобензодиазепины | |
| DK1740584T5 (da) | Kondenseret chinolinderivat og anvendelse deraf | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| MX2011009034A (es) | Formas de profarmaco de inhibidores de cinasa y su uso en la terapia. | |
| NO20004485D0 (no) | Sykloalkenderivater, deres fremstilling og anvendelse | |
| MX2020001235A (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| EA200000400A1 (ru) | Галогензамещенные тетрациклические производные тетрагидрофурана | |
| MX385017B (es) | Conjugados de pirrolobenzodiazepina | |
| EA201301169A1 (ru) | Азотсодержащие гетероциклические соединения и фунгицид для сельского хозяйства или садоводства | |
| DK0420762T3 (da) | Heterocyklisk forbindelse | |
| ECSP10010380A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PL408251A1 (pl) | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A | |
| EP0220878A3 (en) | Ethanolamine compounds | |
| MEP12108A (en) | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them | |
| PL411864A1 (pl) | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy P13 |